Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
In other words, the price has increased by $0.00 from its previous closing price. On the day, 2.59 million shares were traded. MRVI stock price reached its highest trading level at $1.79 during the session, while it also had its lowest trading level at $1.7.
Ratios:
To gain a deeper understanding of MRVI’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.65 and its Current Ratio is at 7.53. In the meantime, Its Debt-to-Equity ratio is 1.16 whereas as Long-Term Debt/Eq ratio is at 1.12.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Robert W. Baird on February 26, 2025, Downgraded its rating to Neutral and sets its target price to $3 from $9 previously.
Goldman Downgraded its Neutral to Sell on December 05, 2024, while the target price for the stock was maintained at $4.25.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jan 31 ’25 when ORESHACK KURT sold 25,000 shares for $5.03 per share. The transaction valued at 125,750 led to the insider holds 167,618 shares of the business.
ORESHACK KURT bought 25,000 shares of MRVI for $125,750 on Jan 31 ’25. On Nov 12 ’24, another insider, DeFord John A, who serves as the Director of the company, bought 17,500 shares for $5.75 each. As a result, the insider paid 100,625 and bolstered with 70,046 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MRVI now has a Market Capitalization of 450716320 and an Enterprise Value of 559098688. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.74 while its Price-to-Book (P/B) ratio in mrq is 0.77. Its current Enterprise Value per Revenue stands at 2.157 whereas that against EBITDA is -23.008.
Stock Price History:
The Beta on a monthly basis for MRVI is 0.30, which has changed by -0.77072537 over the last 52 weeks, in comparison to a change of 0.017286062 over the same period for the S&P500. Over the past 52 weeks, MRVI has reached a high of $11.56, while it has fallen to a 52-week low of $1.66. The 50-Day Moving Average of the stock is -36.16%, while the 200-Day Moving Average is calculated to be -70.86%.
Shares Statistics:
It appears that MRVI traded 3.38M shares on average per day over the past three months and 2447590 shares per day over the past ten days. A total of 141.98M shares are outstanding, with a floating share count of 116.77M. Insiders hold about 18.71% of the company’s shares, while institutions hold 85.98% stake in the company. Shares short for MRVI as of 1743379200 were 13133915 with a Short Ratio of 3.88, compared to 1740700800 on 8822415. Therefore, it implies a Short% of Shares Outstanding of 13133915 and a Short% of Float of 10.879999999999999.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The performance of Maravai LifeSciences Holdings Inc (MRVI) in the stock market is under the watchful eye of 14.0 analysts actively contributing to its current rating.The consensus estimate for the next quarter is -$0.06, with high estimates of -$0.03 and low estimates of -$0.11.
Analysts are recommending an EPS of between -$0.14 and -$0.42 for the fiscal current year, implying an average EPS of -$0.26. EPS for the following year is -$0.19, with 13.0 analysts recommending between -$0.02 and -$0.41.
Revenue Estimates
In the current quarter, 13 analysts expect revenue to total $44.01M. It ranges from a high estimate of $46.8M to a low estimate of $43M. As of the current estimate, Maravai LifeSciences Holdings Inc’s year-ago sales were $64.18MFor the next quarter, 13 analysts are estimating revenue of $48.41M. There is a high estimate of $57.6M for the next quarter, whereas the lowest estimate is $44.6M.
A total of 14 analysts have provided revenue estimates for MRVI’s current fiscal year. The highest revenue estimate was $212.1M, while the lowest revenue estimate was $185M, resulting in an average revenue estimate of $192.75M. In the same quarter a year ago, actual revenue was $259.19MBased on 14 analysts’ estimates, the company’s revenue will be $211.15M in the next fiscal year. The high estimate is $230.43M and the low estimate is $170.78M.
